2008, Number 583
<< Back Next >>
Rev Med Cos Cen 2008; 65 (583)
Cancer Gástrico
Villalobos GMA
Language: Spanish
References: 9
Page: 99-101
PDF size: 130.84 Kb.
ABSTRACT
Gastric cancer is one of the most frequent neoplasms at present. It is the second cause of death in men, and the third in women in the world. Several risk factors are associated with the appearance of gastric cancer. The most popular is Helicobacter Pylori, it has been considered as the predeceding agent of gastric This association have revolutionized the clinical, and therapeutic aspects. This review article about epidemiology, risk factors, incidence of gastric neoplasia was made to prevention and detection of early stomach cancer and maybe it would help many people with this disease.
REFERENCES
American Cancer Society: Cancer Facts and Figures 2005. Atlanta, Ga: American Cancer Society, 2005.
Bayerdorffer E, Miehlke S, Mannes GA, Sommer A, Hochter W. Double blind trial of 120 mg omeprazole plus amoxicillin for H. pylori eradication in duodenal ulcer patients. [abstract]. Gastroenterology 1994; 106:A48.
BIot WJ, Devesa SS, Kneller RW, et al.: Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265 (10): 1287-9, 1991.
CAMPUS DIGITAL. Julio 2005 - Año XVII N° 159.
Fenoglio-Preiser CM, Noffsinger AE, Belli J, et al.: Pathologic and phenotypic features of gastric cancer. Semin Oncol 23 (3): 292-306, 1996.
Gamboa, José. Infección por Helicobacter Pylori y enfermedad ulcerosa péptica. Univ Diag. Artículos de Revisión.3 (1): 20-4. 2003.
Jiménez, Piñon. F., Paniagua, M. Cáncer Gástrico: factores de riesgo. Rev Cubana de Oncología. 1998: 14(3): 171-79.
Kurtz RC, Sherlock P: The diagnosis of gastric cancer. Semin Oncol 12 (1): 11-8, 1985.
Luna P. ¿Cuáles son los porcentajes de erradicación del Helicobacter pylori con esquemas de terapia dual y triple terapia? Acta Gastroenterol Latinoam 1995;26:37-40.
Full text